The Food and Drug Administration has approved the Janus kinase inhibitor ruxolitnib (Opzelura) as topical treatment for nonsegmental vitiligo in children and adults ages 12 years and older.The most common adverse effects are application site acne, application site itching, common cold, headache, urinary tract infection, application site redness, and fever.
Browse by Audience
